Compare EYPT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYPT | HROW |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2005 | N/A |
| Metric | EYPT | HROW |
|---|---|---|
| Price | $16.10 | $47.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $29.60 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 1.1M | 535.4K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $42,339,000.00 | ★ $250,042,000.00 |
| Revenue This Year | N/A | $39.05 |
| Revenue Next Year | N/A | $40.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.83 |
| 52 Week Low | $3.91 | $20.85 |
| 52 Week High | $19.11 | $51.30 |
| Indicator | EYPT | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 60.58 |
| Support Level | $15.97 | $44.48 |
| Resistance Level | $19.11 | $47.90 |
| Average True Range (ATR) | 0.96 | 2.46 |
| MACD | 0.11 | 0.82 |
| Stochastic Oscillator | 46.36 | 68.13 |
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.